Immunoselection in vitro of a non‐metastatic variant from a highly metastatic tumor
- 15 March 1981
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 27 (3) , 381-385
- https://doi.org/10.1002/ijc.2910270318
Abstract
Immunoselection of a non-metastatic variant of the highly metastatic MDAY-D2 tumor of DBA/2 mice was achieved by means of an antiserum directed to the LY6.2 surface marker of MDAY-D2. While the new tumor (MDAY-D2.L61) expresses no detectable LY6.2, other measurable surface markers including H2d, FcR and TAA remain unchanged. The phenotypic behavior of MDAY-D2.L61 is that of a non-metastatic tumor and has remained stable after 1 year of maintenance in vivo and in vitro. Immunoselection can now be used to derive variants with stable phenotypic behavior from heterogeneous parent tumor cell populations.This publication has 18 references indexed in Scilit:
- The pathogenesis of cancer metastasisNature, 1980
- Identity of murine lymphocyte alloantigens DAG, ALA-1, Ly-8, and Ly-6?Immunogenetics, 1979
- Implications of immunological heterogeneity of tumoursNature, 1979
- An Ly-like specificity with extensive nonlymphoid expressionImmunogenetics, 1978
- The Radiolabeling of Lymphocytes and Tumor Cells with 111IndiumExperimental Biology and Medicine, 1978
- Ly-6.2: A new lymphocyte specificity of peripheral T-cellsImmunogenetics, 1977
- Non-metastasising variants selected from metastasising melanoma cellsNature, 1977
- Metastasis Results from Preexisting Variant Cells Within a Malignant TumorScience, 1977
- Selection of Successive Tumour Lines for MetastasisNature New Biology, 1973
- Histocompatibility changes in tumorsJournal of Cellular and Comparative Physiology, 1958